55878-45-0

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dimethoxy-4-pyrimidinecarboxylic acid methyl ester is used as a key intermediate in the synthesis of various pharmaceuticals for its potential role in the development of new drugs. Its unique structure allows for the creation of diverse medicinal compounds with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, 2,6-Dimethoxy-4-pyrimidinecarboxylic acid methyl ester is utilized as a precursor in the production of agrochemicals, contributing to the development of effective pesticides, herbicides, and other crop protection agents.
Used in Organic Synthesis:
2,6-Dimethoxy-4-pyrimidinecarboxylic acid methyl ester serves as a building block in organic synthesis, enabling the creation of a wide range of organic compounds for various applications, including the development of new materials and specialty chemicals.
It is crucial to handle 2,6-Dimethoxy-4-pyrimidinecarboxylic acid methyl ester with care, as it may pose health and environmental risks if not used properly. Proper safety measures and disposal methods should be followed to minimize any potential hazards.

InChI:InChI=1/C8H10N2O4/c1-12-6-4-5(7(11)13-2)9-8(10-6)14-3/h4H,1-3H3

Upstream product

• 67-56-1 methanol 
• 6299-85-0 2,6-dichloropyrimidine-4-carboxylic acid methyl ester 
• 65-86-1 orotic acid 
• 26830-94-4 2,4-dichloropyrimidine-6-carboxylic acid chloride 

Downstream Products

• 664981-80-0 6,7-dihydro-5-hydroxy-3-methoxy-7-methylenepyrrolo[1,2-c]pyrimidin-1(5H)-one 
• 79115-67-6 2,4-dimethoxy-5-(3'-tetrahydropyranyloxyprop-1'-yn)-6-carbomethoxypyrimidine 
• 214899-68-0 ([(Z)-Benzyloxycarbonylimino]-{2-[2-bromo-3-(2,6-dimethoxy-pyrimidin-4-yl)-3-oxo-propyl]-piperidin-1-yl}-methyl)-carbamic acid benzyl ester 
• 214899-64-6 ([(Z)-Benzyloxycarbonylimino]-{2-[3-(2,6-dimethoxy-pyrimidin-4-yl)-3-oxo-propyl]-piperidin-1-yl}-methyl)-carbamic acid benzyl ester 
• 664981-82-2 6,7-dihydro-5-tert-butyldiphenylsilyloxy-3-methoxy-7-methylenepyrrolo[1,2-c]pyrimidin-1(5H)-one 
• 664981-76-4 4-[1-(tert-butyl-diphenyl-silanyloxy)-but-3-enyl]-2,6-dimethoxy-pyrimidine 
• 664981-81-1 6,7-dihydro-5-benzoyloxy-3-methoxy-7-methylenepyrrolo[1,2-c]pyrimidin-1(5H)-one 
• 664981-75-3 benzoic acid 1-(2,6-dimethoxy-pyrimidin-4-yl)-but-3-enyl ester 
• 214899-52-2 phenylmethyl 2-[3-hydroxy-3-[4,6-dimethoxy-2-pyrimidinyl]-1-propynyl]-1(2H)-pyridinecarboxylate 

Relevant academic research and scientific papers

Aminopyrimidine Kinase Inhibitors

Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), casein kinase 2 (CK2), Pim 1, Pim2, Pim3, the TGFβ pathway, the Wnt pathway, the JAK

MGluR5 modulators I

The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.

Total synthesis of (±)-cylindrospermopsin

The first total synthesis of the novel hepatotoxin (±)- cylindrospermopson (1) has been accomplished in 20 steps from 4-methoxy-3- methylpyridine (12) in 3.5% overall yield. The substituted piperidine A ring 19 was generated stereospecifically by a four-step sequence using the addition of trimethylsilylethynylmagnesium bromide to 12 to give 16 and stereospecific addition of vinylcuprate to 16 to form 17. The reaction of diamine 26 with cyanogen bromide produced the cyclic guanidine C ring of 27. The key step in the synthesis was bromination of ketone 31, followed by hydrogenation to liberate the free guanidine, which underwent an intramolecular S(N)2 reaction to form the tetrahydropyrimidine ring B of 32. Further hydrogenation reduced the ketone to yield 42% of 32 containing the fully functionalized tricyclic system and protected hydroxymethyluracil side chain of cylindrospermopsin. Hydrolysis of the pyrimidine in concentrated hydrochloric acid and selective monosulfation completed the synthesis of cylindrospermopsin.